News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Spectrum Pharma (SPPI) Plays With a New Phase III Concept After the FDA Formally Spurns Bladder Cancer Drug



11/18/2016 5:38:56 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
After fielding two failed Phase III studies and watching an FDA committee vote unanimously against an approval, you might say that today’s formal rejection of Spectrum Pharmaceuticals’ bladder cancer treatment apaziquone was something of a foregone conclusion. And Spectrum $SPPI says it’s already considering starting a new Phase III in yet another attempt to win an approval.

Spectrum’s R&D team came up with a post hoc pooled analysis to find the positive data it wanted to see in their two late-stage studies.

Read at Reuters
Read at News Release
Read at News Release
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES